Special Issue "The Asymptomatic Version of Myeloma: MGUS and Smoldering Myeloma"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (29 February 2020).
2. Hematology Department, University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain
3. Institute for Biomedical Research of Salamanca, Salamanca 37007, Spain
Interests: myeloma; asymptomatic myeloma; minimal residual disease; early treatment; novel drugs
All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). MGUS is present in approximately 3%–4% of the general population over the age of 50, and it is associated with a risk of progression to MM or related disorder at a rate of 1% per year. SMM accounts for approximately 10% of all MMs, and the risk or progression to MM is not uniform, ranging from 1% to 10% per year. Both plasma cell disorders are asymptomatic with absence of myeloma-related events, and the cutoff of serum M spike is 3 g/dl or bone marrow plasma cell infiltration of 10% for distinguishing both entities. These criteria are useful in clinical practice, and in the SMM field, some models have emerged to identify different risk subgroups of patients that lead to the proposal of clinical trials in SMM patients at high risk of progression to MM with the attempt of delaying the MM development. Positive results have so far been reported which resulted, in 2014, in the update of the diagnostic criteria for MM, including some SMM patients with an imminent risk of progression to MM identified through the presence of some biomarkers. However, in spite of these major advances, our understanding of the pathogenesis of MGUS and SMM and how they can evolve to MM remains incomplete, and emerging insights in the biology of these preneoplastic lesions and their transition to clinical malignancy are crucial to understand the biology of the disease that can potentially contribute to make clinical decisions about the optimal approach for the management of these premalignant diseases.
This Special Issue aims to deepen the mechanisms involved in the transition from MGUS and SMM to MM and how they can be incorporated to the clinical models and how this approach might impact on the management of MGUS and SMM and which patients would be candidates to preventive versus curative approaches.
Dr. María Victoria Mateos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Monoclonal gammopathy
- Smoldering myeloma
- Prognostic features
- Genetic abnormalities
- Immune system